Neuro Day Presenting Companies
(as of 9/1/2021)
BIORCHESTRA strives to develop disease-modifying therapies in neurodegenerative diseases by focusing on novel RNA therapeutics and brain drug delivery technology to solve the greatest challenges faced in CNS diseases for patients and their families to provide them with a significantly improved quality of life.
Celero Systems is a life sciences company focused on reducing opioid overdose mortality and injury by providing timely, autonomous, life-saving interventions. Celero is developing a revolutionary new ingestible system to automatically detect and reverse opioid overdose. The company is headquartered in the Boston, Massachusetts and led by a veteran team with deep healthcare and technology experience.
Cerevance is a new pharmaceutical company focused on central nervous system diseases. Our strengths include a powerful technology platform, a pipeline of novel discovery-stage and clinical-stage compounds and a proven team. We believe that we are well positioned to deliver life-changing therapeutics for patients who have brain-related disorders while creating value for our employees and shareholders.
Cognoptix is creating and developing a simple, innovative, non-invasive eye scanning test to aid in the early detection and diagnosis of Alzheimer’s Disease. The key to effective preventive therapy and treatment of Alzheimer’s is the creation of an “early warning system” for the disease, before it progresses to the point where treatment options are limited. Cognoptix’ technology has demonstrated successful early clinical results as the company develops its diagnostic platform, which consists of a laser eye scanning device combined with an ophthalmic ointment which specifically identifies Alzheimer’s-related proteins found in the lens of the eye.
At De Oro Devices, the founders were brought together by a common passion for creating innovative technology to improve quality of life for those in need. Our first product, the NexStride, reliably restores mobility to Parkinson's patients experiencing freezing of gait.
EMTensor Inc is the leader in developing electromagnetic tomography (microwave) imaging devices—the safest and smallest of all tomographic modalities. The company includes a subsidiary based in Austria, EMTensor GmbH. Our flagship product development "BrainScanner G4" is the first electromagnetic tomographic brain scanner will be available on the market in 2019. Our unique and patented technology has empowered EMTensor to develop this novel medical imaging device. As the smallest among all available brain tomographic imaging technologies, EMTensor BrainScanner is completely portable and very maneuverable. It can be brought to the stroke patient, eliminating the need for intra- and interhospital transportation of unstable patients. With its lack of ionizing radiation and its favorable ergonomic properties, EMTensor BrainScanner eliminates exposure to harmful radiation and reduces the risk of injury to patients and clinical staff. It fits perfectly into the limited space of an ambulance or emergency room and is easily accommodated in an intensive care unit. As a complement to MRI and CT, EMTensor BrainScanner enables 24/7 head scanning.
EpiVario Inc. is a preclinical stage biotechnology company spun out from the University of Pennsylvania School of Medicine, harnessing neuroepigenetics expertise to treat addiction and anxiety disorders. EpiVario is focused on developing innovative epigenetic therapeutics to treat complex memory-related neuropsychiatric disorders by targeting a newly discovered epigenetic mechanism involved in long term memory. Epivario is thereby developing a first-in-class therapeutic for nicotine addiction.
Healium is a digiceutical for anxiety powered by its technology that allows users to control virtual worlds with their brain patterns and heart rate. Healium is used with the US Air Force and large enterprises and is clinically validated to improve mood in as little as four minutes.
Herantis focuses on disease modifying therapies for debilitating neurodegenerative diseases by restoring the neuronal protective mechanism of proteostasis. CDNF – a biological protein – is Herantis’ lead program and a clinical stage asset; and HER-096 – a synthetic peptidomimetic version of CDNF – is Herantis’ follow-on program. Both assets have the potential to improve neuronal survival and function, and to stop the progression of Parkinson’s and other neurodegenerative disease.
Kinoxis is developing a range of novel therapeutic small molecule compounds for the treatment of substance use disorders and other central nervous system disorders. The company’s lead candidate KNX100 has demonstrated potent anti-addictive and prosocial effects in several different animal models and is on track to commence a Phase 1 study in early 2022. The second series of compounds are at lead selection stage, and target the brain oxytocin system, which is the focus of much interest because of its central role in the positive regulation of social behaviour and its inhibitory effects on addictive behaviours.
Lief tracks and improves heart rate variability, the gold standard biomarker of mental health. In an 8-week clinical trial, Lief's fully remote program significantly reduced symptoms of anxiety in 86% of participants from high to sub-clinical. The Lief program helps patients, providers and payers reach better mental health outcomes with less time and money. The insurance reimbursable product has already collected more than 1 billion heartbeats, jumpstarting an internal pipeline of AI-driven digital mental health diagnostics and therapeutics.
MitoImmune Therapeutics Inc. is an innovative biotechnology company focusing on development of first-in-class therapeutics targeting mitochondria dysfunctions and necrosis. Based on our proprietary technology platform, we are discovering, developing and commercializing breakthrough treatments for Neurodegenerative Diseases. MitoImmune was founded in 2018 and successfully raised the series A and series B.
NeuroDex is a leading developer of exosome-of-origin based diagnostics. NeuroDex's integrative research platform, called ExoSORT™, combines bioinformatics and state-of-the-art laboratory processes. Building on all of its proprietary platform technologies (including ExoSORT™), NeuroDex develops a full range of exosome-of-origin, minimally invasive, blood-based diagnostic, prognostic, pharmacodynamic, and theranostic tools.
NeuroGeneces is a seed-stage, woman-led startup providing a scientifically-proven safe and effective way to enhance memory through acoustic stimulation of memory consolidation during sleep. In addition, our system will provide early identification of individuals at risk for neurodegenerative diseases to enable timely intervention. Our prototype is in trials and preliminary results are positive.
Neurovine is changing the way concussion patients recover using real-time data and machine learning to personalize your path to recovery. Our proprietary technology lets you return to life without the fear of regression in your recovery process.
SCYiBL is an emotional regulating software used to confront and tackle stressful situations. Users are able to train their brain to shift from positive to negative mode in order for them to focus and perform with less distractions while they are rewiring their brain.
Sinntaxis AB is working with a first in class treatment aiding stroke recovery. This is done with a repositioned, phase II ready drug candidate (ex AstraZeneca), and the company is preparing for a clinical Proof of Concept study in post-acute stroke recovery.
STALICLA SA is a Swiss clinical stage biopharmaceutical company leading omics-based precision medicine drug development for patients with neurodevelopmental disorders (NDDs), with a first application in Autism Spectrum Disorder (ASD).
StimScience is using neuroscience to fix sleep. We’re building a sleep wearable that stimulates your brain to directly help you to achieve a deeper, higher-quality night's sleep. With seed funding from Khosla Ventures, we've spent the last 2+ years developing the neuroscience behind our device in our sleep lab in Berkeley, and we're seeing incredibly promising results. With a 15-minute, personalized stim session at bedtime, our study participants have an average improvement over sham in sleep onset of over 50%, and in sleep efficiency of 10-15% - better than any sleeping pill or behavioral therapy!
TTM Therapeutics is developing two distinct multi-indication drug platforms (acute use IV and chronic use oral). TTM-001 is clinical stage Phase 1-2 for its lead cardiac indication, with multiple neuro indications being prepared for entry into the clinic (TBI, Stroke, SCI). TTM-002 is in early-stage development for chronic use indications (mild to moderate concussion, TBI and other indications).